Patents by Inventor Claire Y. H. Kinney

Claire Y. H. Kinney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8067565
    Abstract: The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV1 strain.
    Type: Grant
    Filed: December 8, 2009
    Date of Patent: November 29, 2011
    Assignees: Sanofi Pasteur, Centers For Disease Control and Prevention
    Inventors: Richard Kinney, Claire Y. H. Kinney, Véronique Barban, Jean Lang, Bruno Guy
  • Patent number: 8025887
    Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.
    Type: Grant
    Filed: October 28, 2009
    Date of Patent: September 27, 2011
    Assignees: The United States of America as represented by the Department of Health and Human Services, Centers for Disease Control and Prevention, Mahidol University
    Inventors: Richard M. Kinney, Claire Y. H. Kinney, Duane J. Gubler, Siritorn Butrapet, Natth Bhamarapravati
  • Publication number: 20110150771
    Abstract: The disclosure provides chimeric West Nile/Dengue viruses comprising non-coding regions, non-structural proteins, and a C protein from a West Nile virus and prM and E proteins from a Dengue virus. Also disclosed are methods of using the chimeric viruses in diagnosis of Dengue viral infection, assessment of candidate Dengue virus vaccine efficacy, and production of Dengue prM and E proteins.
    Type: Application
    Filed: April 27, 2009
    Publication date: June 23, 2011
    Inventors: Claire Y.H. Kinney, Eric Thomas Beck, Richard M. Kinney
  • Publication number: 20100255030
    Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.
    Type: Application
    Filed: October 28, 2009
    Publication date: October 7, 2010
    Inventors: Richard M. Kinney, Claire Y.H. Kinney, Siritorn Butrapet, Duane J. Gubler, Natth Bhamarapravati
  • Publication number: 20100174057
    Abstract: The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain.
    Type: Application
    Filed: December 8, 2009
    Publication date: July 8, 2010
    Inventors: Richard Kinney, Claire Y.H. Kinney, Véronique Barban, Jean Lang, Bruno Guy
  • Publication number: 20100137571
    Abstract: The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV1 strain.
    Type: Application
    Filed: December 8, 2009
    Publication date: June 3, 2010
    Inventors: RICHARD KINNEY, CLAIRE Y.H. KINNEY, VÉRONIQUE BARBAN, JEAN Lang, BRUNO GUY
  • Patent number: 7641908
    Abstract: The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells. The invention further relates to a vaccine composition which comprises a VDV2 strain.
    Type: Grant
    Filed: June 15, 2006
    Date of Patent: January 5, 2010
    Assignees: Sanofi Pasteur, Center for Disease Control and Prevention
    Inventors: Richard Kinney, Claire Y. H. Kinney, Véronique Barban, Jean Lang, Bruno Guy
  • Patent number: 7641909
    Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural protein genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.
    Type: Grant
    Filed: August 18, 2006
    Date of Patent: January 5, 2010
    Assignee: The United States of America as represented by the Secretary, Department of Health and Human Services, Certers for Disease Control and Prevention
    Inventors: Richard M. Kinney, Claire Y. H. Kinney, Duane J. Gubler, Siritorn Butrapet, Natth Bhamarapravati
  • Patent number: 7641907
    Abstract: The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells. The invention further relates to a vaccine composition which comprises a VDV1 strain.
    Type: Grant
    Filed: June 9, 2006
    Date of Patent: January 5, 2010
    Assignees: Sanofi Pasteur, Center for Disease Control and Prevention
    Inventors: Richard Kinney, Claire Y. H. Kinney, Véronique Barban, Jean Lang, Bruno Guy
  • Publication number: 20090010961
    Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural protein genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.
    Type: Application
    Filed: August 18, 2006
    Publication date: January 8, 2009
    Inventors: Richard M. Kinney, Claire Y.H. Kinney, Duane J. Gubler, Siritorn Butrapet, Natth Bhamarapravati
  • Patent number: 7094411
    Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural protein genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.
    Type: Grant
    Filed: February 16, 2001
    Date of Patent: August 22, 2006
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Richard M. Kinney, Claire Y. H. Kinney, Duane J. Gubler, Siritorn Butrapet, Natth Bhamarapravati